Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Key Highlights
- ➤Nuvectis will report Q3 2026 financial results on November 4, 2026
- ➤Nuvectis will host an 8:00 AM ET conference call and webcast
- ➤NXP100 ciprocopan was recently approved in China for previously untreated PNH patients
Expert Statements
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis Pharma
“Nuvectis Pharma, Inc.”
Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
Conference Call and Webcast Information: Date: 8:00 AM ET, Wednesday, November 4, 2026 Participant Dial-In (U.S.): 1-877-407-0752 Participant Dial-In (International): 1-201-389-0912 Conference ID: 13763643 Webcast Access: Please click here
Get started
Create a free account to read the full story.